This randomized, double blind, two attack, placebo controlled, crossover st udy explored the efficacy and tolerability of rizatriptan 10 mg compared with su matriptan 50 mg as well as rizatriptan 5 mg compared with su...This randomized, double blind, two attack, placebo controlled, crossover st udy explored the efficacy and tolerability of rizatriptan 10 mg compared with su matriptan 50 mg as well as rizatriptan 5 mg compared with sumatriptan 25 mg in t he acute treatment of migraine. Following randomization to one of six possible t reatment sequences, patients (n=1447) treated two sequential attacks, of moderat e or severe intensity, separated by at least 5 days. Patients assessed pain seve rity, migraine asso ciated symptoms, and functional disability at 0.5, 1, 1.5, and 2 h post treatment. Compared with placebo, all treatments were effective. O n the primary endpoint of time to pain relief, rizatriptan 10 mg was not statist ically different from sumatriptan 50 mg [odds ratio (OR) 1.10, P = 0.161], and r izatriptan 5 mg was statistically superior to sumatriptan 25 mg (OR 1.22, P=0.00 7). In general, rizatriptan 10 mg and 5 mg treatment resulted in improvement com pared with the corresponding doses of sumatriptan on measures of pain severity, migraine symptoms, and functional disability and the 5 mg dose reached statisti cal significance on almost all measures. All treatments were generally well tole rated.展开更多
文摘This randomized, double blind, two attack, placebo controlled, crossover st udy explored the efficacy and tolerability of rizatriptan 10 mg compared with su matriptan 50 mg as well as rizatriptan 5 mg compared with sumatriptan 25 mg in t he acute treatment of migraine. Following randomization to one of six possible t reatment sequences, patients (n=1447) treated two sequential attacks, of moderat e or severe intensity, separated by at least 5 days. Patients assessed pain seve rity, migraine asso ciated symptoms, and functional disability at 0.5, 1, 1.5, and 2 h post treatment. Compared with placebo, all treatments were effective. O n the primary endpoint of time to pain relief, rizatriptan 10 mg was not statist ically different from sumatriptan 50 mg [odds ratio (OR) 1.10, P = 0.161], and r izatriptan 5 mg was statistically superior to sumatriptan 25 mg (OR 1.22, P=0.00 7). In general, rizatriptan 10 mg and 5 mg treatment resulted in improvement com pared with the corresponding doses of sumatriptan on measures of pain severity, migraine symptoms, and functional disability and the 5 mg dose reached statisti cal significance on almost all measures. All treatments were generally well tole rated.
